ArticleOncoTargets and therapy2018
Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Identification of tumor-promoting functions of the Homeobox family transcription factor MSX1 in cervical cancer.Cell death discovery · 2026Article
- Long-Chain Fatty Acids Inhibit Myeloid-Derived Suppressor Cells to Delay Tumor Progression.Current issues in molecular biology · 2026Article
- In Vitro Effects of Cabazitaxel and Menadione on Cell Growth, Metabolism, and Transcriptomic Profile of Human Prostate Cancer Cell Lines.Prostate cancer · 2026Article
- TKI resistance related genes in LUAD predict patient prognosis and tumor immune microenvironment with LHX2 as a hub gene.Discover oncology · 2025Article
- Manipulation with Mutational Status of VHL Regulates Hypoxic Metabolism and Pro-Angiogenic Phenotypes in ccRCC Caki-1 Cells.International journal of molecular sciences · 2025Article
- Study Deciphering the Crucial Involvement of Notch Signaling Pathway in Human Cancers.Endocrine, metabolic & immune disorders drug targets · 2024Review
- MSX1-expression during the different phases in healthy human endometrium.Archives of gynecology and obstetrics · 2023Article
- Research on Predicting the Occurrence of Hepatocellular Carcinoma Based on Notch Signal-Related Genes Using Machine Learning Algorithms.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Article
- Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma.Cancers · 2022Review
- In silico identification of novel biomarkers for key players in transition from normal colon tissue to adenomatous polyps.PloS one · 2022Article
- Functional New Transcription Factors (TFs) Associated with Cervical Cancer.Journal of healthcare engineering · 2022Article
- A single-nucleotide-polymorphism in the 5'-flanking region ofTherapeutic advances in medical oncology · 2022Article
- Modeling cartilage pathology in mucopolysaccharidosis VI using iPSCs reveals early dysregulation of chondrogenic and metabolic gene expression.Frontiers in bioengineering and biotechnology · 2022Article
- PAX9 Determines Epigenetic State Transition and Cell Fate in Cancer.Cancer research · 2021Article
- A narrative review of the roles of muscle segment homeobox transcription factor family in cancer.Annals of translational medicine · 2021Review
- Development of Potential Prognostic Biomarkers Based on DNA Methylation-Driven Genes for Patients with Endometrial Cancer.International journal of general medicine · 2021Article
- A Novel Transcription Factor-Based Prognostic Signature in Endometrial Cancer: Establishment and Validation.OncoTargets and therapy · 2021Article
- Systematic Investigation of DNA Methylation Associated With Platinum Chemotherapy Resistance Across 13 Cancer Types.Frontiers in pharmacology · 2021Article
- NOVA1-Mediated SORBS2 Isoform Promotes Colorectal Cancer Migration by Activating the Notch Pathway.Frontiers in cell and developmental biology · 2021Article
- Prediction of the Mechanisms by Which Quercetin Enhances Cisplatin Action in Cervical Cancer: A Network Pharmacology Study and Experimental Validation.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe objectives of this study were to investigate the expression of PATIENTS AND
methodsSemi-quantitative and quantitative reverse transcription-polymerase chain reactions were used to investigate the expression levels of
results
conclusionMSX1 appears to be a functional tumor suppressor that regulates tumorigenesis in cervical cancer by antagonizing Notch signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.